1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tagliamonte M, Petrizzo A, Tornesello ML,
Ciliberto G, Buonaguro FM and Buonaguro L: Combinatorial
immunotherapy strategies for hepatocellular carcinoma. Curr Opin
Immunol. 39:103–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Thomas MB and Zhu AX: Hepatocellular
carcinoma: The need for progress. J Clin Oncol. 23:2892–2899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Scheel C, Eaton EN, Li SH, Chaffer CL,
Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, et al:
Paracrine and autocrine signals induce and maintain mesenchymal and
stem cell states in the breast. Cell. 145:926–940. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kladney RD, Bulla GA, Guo L, Mason AL,
Tollefson AE, Simon DJ, Koutoubi Z and Fimmel CJ: GP73, a novel
Golgi-localized protein upregulated by viral infection. Gene.
249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Xu Z, Liu L, Pan X, Wei K, Wei M, Liu L,
Yang H and Liu Q: Serum Golgi protein 73 (GP73) is a diagnostic and
prognostic marker of chronic HBV liver disease. Medicine
(Baltimore). 94:e6592015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wei H, Zhang J, Li H, Ren H, Hao X and
Huang Y: GP73, a new marker for diagnosing HBV-ACLF in population
with chronic HBV infections. Diagn Microbiol Infect Dis. 79:19–24.
2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wei H, Hao X, Li B and Li X, Hou J, Qiao
Y, Zhang R and Li X: GP73 is a potential marker for evaluating AIDS
progression and antiretroviral therapy efficacy. Mol Biol Rep.
40:6397–6405. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang Z, Zhang Y, Wang Y, Xu L and Xu W:
Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate
biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular
carcinoma. Onco Targets Ther. 9:123–129. 2015.PubMed/NCBI
|
12
|
Xu WJ, Guo BL, Han YG, Shi L and Ma WS:
Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in
hepatocellular carcinomas with low AFP levels. Tumour Biol.
35:12069–12074. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kristiansen G, Fritzsche FR, Wassermann K,
Jäger C, Tölls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M,
et al: GOLPH2 protein expression as a novel tissue biomarker for
prostate cancer: Implications for tissue-based diagnostics. Br J
Cancer. 99:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Varambally S, Laxman B, Mehra R, Cao Q,
Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A,
Yu J, et al: Golgi protein GOLM1 is a tissue and urine biomarker of
prostate cancer. Neoplasia. 10:1285–1294. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wei S, Dunn TA, Isaacs WB, De Marzo AM and
Luo J: GOLPH2 and MYO6: Putative prostate cancer markers localized
to the Golgi apparatus. Prostate. 68:1387–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang F, Gu Y, Li X, Wang W, He J and Peng
T: Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung
adenocarcinoma tissue. Clin Biochem. 43:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chen LG, Wang HJ, Yao HB, Guan TP, Wu F,
He XJ, Ma YY, Tao HQ and Ye ZY: GP73 is down-regulated in gastric
cancer and associated with tumor differentiation. World J Surg
Oncol. 11:132–139. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mao Y, Yang H, Xu H, Lu X, Sang X, Du S,
Zhao H, Chen W, Xu Y, Chi T, et al: Golgi protein 73 (GOLPH2) is a
valuable serum marker for hepatocellular carcinoma. Gut.
59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Bao YX, Yang Y, Zhao HR, Mao R, Xiao L,
Zhang YF, Aisiker T and Wen H: Clinical significance and diagnostic
value of Golgi-protein 73 in patients with early-stage primary
hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 35:505–508.
2013.(In Chinese). PubMed/NCBI
|
20
|
Dai M, Chen X, Liu X, Peng Z, Meng J and
Dai S: Diagnostic value of the combination of Golgi protein 73 and
alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis.
PLoS One. 10:e01400672015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang J, Li J, Dai W, Wang F, Shen M, Chen
K, Cheng P, Zhang Y, Wang C, Zhu R, et al: Golgi protein 73 as a
biomarker for hepatocellular carcinoma: A diagnostic meta-analysis.
Exp Ther Med. 9:1413–1420. 2015.PubMed/NCBI
|
22
|
Hu JS, Wu DW, Liang S and Miao XY: GP73, a
resident Golgi glycoprotein, is sensibility and specificity for
hepatocellular carcinoma of diagnosis in a hepatitis B-endemic
Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Bao YX, Cao Q, Yang Y, Mao R, Xiao L,
Zhang H, Zhao HR and Wen H: Expression and prognostic significance
of golgiglycoprotein73 (GP73) with epithelial-mesenchymal
transition (EMT) related molecules in hepatocellular carcinoma
(HCC). Diagn Pathol. 8:197–203. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kladney RD, Cui X, Bulla GA, Brunt EM and
Fimmel CJ: Expression of GP73, a resident Golgi membrane protein,
in viral and nonviral liver disease. Hepatology. 35:1431–1440.
2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bachert C, Fimmel C and Linstedt AD:
Endosomal trafficking and proprotein convertase cleavage of cis
Golgi protein GP73 produces marker for hepatocellular carcinoma.
Traffic. 8:1415–1423. 2007. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zhang YL, Zhang YC, Han W, Li YM, Wang GN,
Yuan S, Wei FX, Wang JF, Jiang JJ and Zhang YW: Effect of GP73
silencing on proliferation and apoptosis in hepatocellular cancer.
World J Gastroenterol. 20:11287–11296. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G,
Lu X, Sang X, Zhao H, Zhong S, et al: Increased Golgi protein 73
expression in hepatocellular carcinoma tissue correlates with tumor
aggression but not survival. J Gastroenterol Hepatol. 26:1207–1212.
2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh
YC, Lei HJ, Hsiao M, Huang SF, Huang CY and Chau GY: Expression of
GOLM1 correlates with prognosis in human hepatocellular carcinoma.
Ann Surg Oncol. 20:(Suppl 3). S616–S624. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Liu Y, Zhang X, Sun T, Jiang J, Li Y, Chen
M, Wei Z, Jiang W and Zhou L: Knockdown of Golgi phosphoprotein 2
inhibits hepatocellular carcinoma cell proliferation and motility.
Oncotarget. 7:21404–21415. 2016.PubMed/NCBI
|
30
|
Jin D, Tao J, Li D, Wang Y, Li L, Hu Z,
Zhou Z, Chang X, Qu C and Zhang H: Golgi protein 73 activation of
MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget.
6:33523–33533. 2015.PubMed/NCBI
|